Neurotechnology company Cognito Therapeutics announced a partnership with Aetion to develop a validated predictive model that will help identify patients with rapidly progressing mild cognitive impairment and Alzheimer’s disease.
The artificial intelligence model, built on roughly 5 million commercial and Medicare claims, will enable population-level risk and cost assessments for payers and integrated health systems, clinical study population, enrichment and, once it becomes available, will support deployment of Cognito’s intervention to AD patients with the highest risk for rapid